VHCP Management II’s Coherus Oncology CHRS Stock Holding History

VHCP Management II’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-95,276	Closed	-$2.02M	–	21
2017 Q1	$2.02M	Sell	95,276 -34,353	-27%	-$845K	0.82%	13
2016 Q4	$3.65M	Hold	129,629	–	–	1.75%	12
2016 Q3	$3.47M	Sell	129,629 -129,630	-50%	-$3.54M	1.78%	14
2016 Q2	$4.38M	Hold	259,259	–	–	2.64%	12
2016 Q1	$5.5M	Hold	259,259	–	–	3.62%	9
2015 Q4	$5.95M	Buy	+259,259	New	+$6.67M	4.89%	7

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VHCP Management II's CHRS Position: Q2 2017 in Review

VHCP Management II sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 95,276 shares — an estimated $2.02M sold.

VHCP Management II first reported a position in CHRS in Q4 2015 and held it in 6 quarters. The position peaked at $5.95M in Q4 2015. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

VHCP Management II reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
VHCP Management II sold 95,276 Coherus Oncology shares in Q2 2017, an estimated $2.02M.
VHCP Management II first reported a position in Coherus Oncology in Q4 2015 and held it in 6 quarters.
VHCP Management II's Coherus Oncology position peaked at $5.95M in Q4 2015.
106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on VHCP Management II's 13F filing for Q2 2017, filed 11 Aug 2017.